ERBB2 and cancer: According to TIMER analysis, TRIP-Br-3 is found to be overexpressed in several cancers, including BRCA, BLCA, CHOL, ESCA, HNSC, liver hepatocellular carcinoma (LIHC), and LUSC, whereas significantly under or lower expressed in luminal/basal/HER2-positive BRCA and KICH than normal tissues.